Sigwadhi Lovemore N, Tamuzi Jacques L, Zemlin Annalise E, Chapanduka Zivanai C, Allwood Brian W, Koegelenberg Coenraad F, Irusen Elvis M, Lalla Usha, Ngah Veranyuy D, Yalew Anteneh, Savieri Perseverence, Fwemba Isaac, Jalavu Thumeka P, Erasmus Rajiv T, Matsha Tandi E, Zumla Alimuddin, Nyasulu Peter S
Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University and NHLS Tygerberg Hospital, Cape Town, South Africa.
IJID Reg. 2022 Dec;5:154-162. doi: 10.1016/j.ijregi.2022.10.004. Epub 2022 Nov 1.
The aim of this study was to identify clinical and laboratory phenotype distribution patterns and their usefulness as prognostic markers in COVID-19 patients admitted to the intensive care unit (ICU) at Tygerberg Hospital, Cape Town.
A latent class analysis (LCA) model was applied in a prospective, observational cohort study. Data from 343 COVID-19 patients were analysed. Two distinct phenotypes (1 and 2) were identified, comprising 68.46% and 31.54% of patients, respectively. The phenotype 2 patients were characterized by increased coagulopathy markers (D-dimer, median value 1.73 ng/L vs 0.94 ng/L; < 0.001), end-organ dysfunction (creatinine, median value 79 µmol/L vs 69.5 µmol/L; < 0.003), under-perfusion markers (lactate, median value 1.60 mmol/L vs 1.20 mmol/L; < 0.001), abnormal cardiac function markers (median N-terminal pro-brain natriuretic peptide (NT-proBNP) 314 pg/ml vs 63.5 pg/ml; < 0.001 and median high-sensitivity cardiac troponin (Hs-TropT) 39 ng/L vs 12 ng/L; < 0.001), and acute inflammatory syndrome (median neutrophil-to-lymphocyte ratio 15.08 vs 8.68; < 0.001 and median monocyte value 0.68 × 10/L vs 0.45 × 10/L; < 0.001).
The identification of COVID-19 phenotypes and sub-phenotypes in ICU patients could help as a prognostic marker in the day-to-day management of COVID-19 patients admitted to the ICU.
本研究旨在确定开普敦泰格伯格医院重症监护病房(ICU)收治的新冠肺炎患者的临床和实验室表型分布模式及其作为预后标志物的效用。
在一项前瞻性观察队列研究中应用了潜在类别分析(LCA)模型。分析了343例新冠肺炎患者的数据。确定了两种不同的表型(1和2),分别占患者的68.46%和31.54%。表型2患者的特征为凝血功能障碍标志物升高(D-二聚体,中位数1.73 ng/L对0.94 ng/L;<0.001)、终末器官功能障碍(肌酐,中位数79 μmol/L对69.5 μmol/L;<0.003)、灌注不足标志物(乳酸,中位数1.60 mmol/L对1.20 mmol/L;<0.001)、心脏功能异常标志物(N端脑钠肽前体(NT-proBNP)中位数314 pg/ml对
63.5 pg/ml;<0.001以及高敏心肌肌钙蛋白(Hs-TropT)中位数39 ng/L对12 ng/L;<0.001),以及急性炎症综合征(中性粒细胞与淋巴细胞比例中位数15.08对8.68;<0.001以及单核细胞值中位数0.68×10/L对0.45×10/L;<0.001)。
识别ICU患者的新冠肺炎表型和亚表型有助于作为ICU收治的新冠肺炎患者日常管理中的预后标志物。